Stakeholder Interaction​

After consolidating sustainability-related matters and feedback from various departments, the OBI Pharma Sustainability Executive Committee referred to the AA1000 Stakeholder Engagement Standard (SES) and industry practices in the biotechnology sector. Based on criteria such as dependency, responsibility, influence, diversity of perspectives, and tension of concern, the Committee identified eight key stakeholder groups for OBI Pharma: shareholders/investors/securities firms, government agencies, suppliers, employees, medical institutions (healthcare professionals), industry associations, academic and research institutions, and banks.
Through anonymous public surveys, interviews, daily interactions, and observations, the Committee gained insights into stakeholders’ expectations and their concerns regarding the company’s sustainability efforts. In addition to providing timely responses, these findings serve as a reference for advancing corporate sustainability. The OBI Pharma Sustainability Executive Committee annually and regularly presents the results of stakeholder engagement in the annual sustainability report to the Sustainability Development Committee and subsequently to the Board of Directors.

The company has established a diverse range of mechanisms for interacting and communicating with stakeholders, utilizing various channels to understand their expectations and concerns regarding the company's sustainable development. In response, the company not only addresses these concerns promptly but also incorporates them into its corporate sustainability development plans. OBI Pharma's Sustainability Development Executive Committee holds annual internal meetings to identify and analyze sustainability topics. The conclusions from stakeholder engagements and the company's sustainability achievements are disclosed in the OBI Pharma Sustainability Report, which is submitted to the Board of Directors for guidance and review.